ArticleScientific reports2025
Composite dietary antioxidant index is inversely associated with all-cause, cardiovascular and cancer mortality in adults with hyperlipidemia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
To explore the association between the Composite Dietary Antioxidant Index (CDAI) and all-cause, cardiovascular disease (CVD), and cancer mortality in U.S. adults with hyperlipidemia, and to assess the potential mediating role of inflammation-related biomarkers in this association. 25,383 patients with hyperlipidemia from the 2001-2018 National Health and Nutrition Examination Survey (NHANES) were included. The association between CDAI and mortality was assessed using weighted Cox regression models, Kaplan-Meier survival curves, subgroup analyses, and sensitivity analyses. Mediation analysis evaluated the roles of leucocytes, neutrophils, monocytes, lymphocytes, and the systemic inflammatory response index (SIRI). A total of 3,810 all-cause deaths, 1,218 CVD deaths, and 883 cancer deaths were recorded during the follow-up period. Fully adjusted models showed that highest CDAI (Q4 group) compared to the lowest quartile (Q1) was associated with a lower risk of all-cause (HR = 0.79, 95% CI: 0.68-0.91, P = 0.001), CVD (HR = 0.73, 95% CI: 0.55-0.96, P = 0.026) and cancer (HR = 0.72, 95% CI: 0.55-0.93, P = 0.011) mortality. The protective effect of vitamin E on the risk of death was most significant. The results of subgroup and sensitivity analyses were robust. Inflammatory indicators mediated the association between CDAI and mortality, with a range of changes from 1.11% to 4.12%. Higher CDAI, especially vitamin E intake, was independently associated with a significant reduction in all-cause, CVD, and cancer mortality in hyperlipidemic patients. Inflammation may partially mediate this association, with a modest mediation effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.